zenocutuzumab NRG1
Selected indexed studies
- Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. (N Engl J Med, 2025) [PMID:39908431]
- Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. (Cancer Discov, 2022) [PMID:35135829]
- The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. (Future Oncol, 2024) [PMID:38348690]
_Worker-drafted node — pending editorial review._
Connections
zenocutuzumab NRG1 is a side effect of
Sources
- Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. (2025) pubmed
- Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. (2022) pubmed
- The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. (2024) pubmed
- The use of zenocutuzumab for NRG1 fusion-positive tumors. (2024) pubmed
- Zenocutuzumab: First Approval. (2025) pubmed
- Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours. (2025) pubmed
- Zenocutuzumab Shines in PDAC. (2021) pubmed
- NRG1 fusions: Biology to therapy. (2021) pubmed
- NRG1 Fusions: The New Kid on the Block. (2025) pubmed
- eNRGy: Making progress toward a future for NRG1 fusion-positive cancer. (2025) pubmed